Synonym
Canventol; DL-Canventol
IUPAC/Chemical Name
2-Cyclohexen-1-ol, 2-(1-methylethyl)-4-(1-methylethylidene)-, (+-)-
InChi Key
CYOJESZRZNCQEV-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H20O/c1-8(2)10-5-6-12(13)11(7-10)9(3)4/h7,9,12-13H,5-6H2,1-4H3
SMILES Code
OC1C(C(C)C)=C/C(CC1)=C(C)\C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
180.29
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Yun TK. Update from Asia. Asian studies on cancer chemoprevention. Ann N Y Acad Sci. 1999;889:157-92. doi: 10.1111/j.1749-6632.1999.tb08734.x. PMID: 10668493.
2: Biswas DK, Mhashilkar AM, Ewaniuk DS, Pezza JA, Oh LM, Kannangara GS, Tius MA, Pardee AB. Inhibition of HIV-1 replication by combination of a novel inhibitor of TNF-alpha with AZT. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 15;18(5):426-34. doi: 10.1097/00042560-199808150-00003. PMID: 9715838.
3: Komori A, Okabe S, Suganuma M, Kerr MA, Busch-Petersen J, Oh LM, Zhuo J, Kannangara GS, Zou X, Tius MA, Fujiki H. Anti-tumor promoting activity of canventol and its synthetic analogs through inhibition of protein isoprenylation. Jpn J Cancer Res. 1996 Sep;87(9):875-81. doi: 10.1111/j.1349-7006.1996.tb02114.x. PMID: 8878447; PMCID: PMC5921199.
4: Suganuma M, Okabe S, Sueoka E, Iida N, Komori A, Kim SJ, Fujiki H. A new process of cancer prevention mediated through inhibition of tumor necrosis factor alpha expression. Cancer Res. 1996 Aug 15;56(16):3711-5. PMID: 8706012.
5: Biswas DK, Tius MA, Zhuo J, Pardee AB. Canventol inhibits HIV-1 replication by Tat-induced Tar-independent mechanism. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):120-7. doi: 10.1097/00042560-199606010-00004. PMID: 8680882.
6: Fujiki H, Suganuma M, Komori A, Yatsunami J, Okabe S, Ohta T, Sueoka E. A new tumor promotion pathway and its inhibitors. Cancer Detect Prev. 1994;18(1):1-7. PMID: 8162603.
7: Komori A, Suganuma M, Okabe S, Zou X, Tius MA, Fujiki H. Canventol inhibits tumor promotion in CD-1 mouse skin through inhibition of tumor necrosis factor alpha release and of protein isoprenylation. Cancer Res. 1993 Aug 1;53(15):3462-4. PMID: 8339247.
